- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | 2.059 | AFX News | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| Mi | JPMorgan downgrades Day One Biopharmaceuticals stock rating on Servier acquisition | 4 | Investing.com | ||
| Di | This Day One Biopharmaceuticals Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday | 2 | Benzinga.com | ||
| Mo | Servier acquires International Biotech's Day One Biopharmaceuticals for USD2.5 billion | 3 | Alliance News | ||
| Mo | Intnl. Biotechnology - Portfolio company Day One Biopharmaceuticals acquired by Servier | 1 | RNS | ||
| 07.03. | Key deals this week: Diana Shipping, Day One BioPharmaceuticals, Hudbay Minerals and more | 24 | Seeking Alpha | ||
| DAY ONE BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 07.03. | Day One Biopharmaceuticals (DAWN) Climbs to 3-Year High on $2.5-Billion Merger | 1 | Insider Monkey | ||
| 06.03. | Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma | 1 | MedCity News | ||
| 06.03. | Servier Acquiring Day One Biopharmaceuticals For About $2.5 Billion | 1 | pulse2.com | ||
| 06.03. | Servier Acquires Day One Biopharmaceuticals, Expanding Rare Oncology Portfolio | 2 | Contract Pharma | ||
| 06.03. | Servier to build cancer drug pipeline with $2.5B purchase of Day One Biopharmaceuticals | 1 | BioPharma Dive | ||
| 06.03. | Oppenheimer reiterates Day One Biopharmaceuticals stock rating on Servier deal | 2 | Investing.com | ||
| 06.03. | TD Cowen downgrades Day One Biopharmaceuticals stock on Servier deal | 3 | Investing.com | ||
| 06.03. | Marvell Technology, Day One Biopharmaceuticals, Samsara And Other Big Stocks Moving Higher On Friday | 5 | Benzinga.com | ||
| 06.03. | Jones Trading cuts Day One Biopharmaceuticals stock rating on Servier acquisition | 1 | Investing.com | ||
| 06.03. | Jones Trading stuft Day One Biopharmaceuticals nach Servier-Übernahme herab | 1 | Investing.com Deutsch | ||
| 06.03. | Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio | 695 | PR Newswire | Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. Transaction represents... ► Artikel lesen | |
| 06.03. | Day One Biopharma to be acquired by Servier for $2.5B | 9 | Seeking Alpha | ||
| 06.03. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 06.03. | Day One Biopharmaceuticals, Inc.: Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio | 771 | GlobeNewswire (Europe) | Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs Transaction represents total... ► Artikel lesen |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,95 | +0,44 % | Opening Bell: BioNTech, Hewlett Packard Enterprise, NIO, Oracle, Adobe | Die US-Börsen haben am Montag im Handelsverlauf ins Plus gedreht. Der Dow Jones schloss 0,50 Prozent höher, nachdem er zunächst schwächer gestartet war. Der Nasdaq Composite legte sogar 1,38 Prozent... ► Artikel lesen | |
| AMGEN | 321,50 | +0,23 % | Wenn das eigene Immunsystem die Augen angreift / Biotechnologieunternehmen Amgen setzt auf Forschung für Patient:innen mit seltenen Erkrankungen | München (ots) - Die endokrine Orbitopathie ist eine seltene und potenziell sehkraftbedrohende Autoimmunerkrankung. Mit einem zielgerichteten Forschungsansatz nach seinem "Biology first"-Prinzip baut... ► Artikel lesen | |
| NOVAVAX | 8,923 | -0,34 % | Jefferies reiterates Buy on Novavax stock, cites adjuvant platform | ||
| BIOGEN | 160,90 | -0,12 % | Biogen Inc.: Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy | New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapySalanersen... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 43,000 | +0,47 % | CRISPR Therapeutics AG: CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering | ZUG, Switzerland and BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the "Company") today announced the pricing of $550 million aggregate principal amount of its... ► Artikel lesen | |
| VIKING THERAPEUTICS | 31,280 | -0,03 % | Jefferies bestätigt Kaufempfehlung für Viking Therapeutics mit Kursziel von 101 US-Dollar | ||
| MAINZ BIOMED | 0,720 | -0,80 % | Quantum Cyber (f/k/a Mainz Biomed) Announces Stock Ticker Symbol Change to NASDAQ: QUCY | BERKELEY, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: QUCY) doing business as Quantum Cyber, today announced, effective upon the commencement of trading on March 12, 2026... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,130 | -0,36 % | Intellia Therapeutics auf der Leerink-Konferenz: Gen-Editing-Therapie Lonbo-Z mit hohem Margenpotenzial | ||
| TEMPUS AI | 43,800 | 0,00 % | Cathie Wood's ARK sells LY Corp stock, buys Tempus AI | ||
| BIOCRYST PHARMACEUTICALS | 7,252 | +0,11 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Full Year 2025 Financial Results and Provides Business Update | -Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 51,16 | -0,12 % | BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents | ||
| EXELIXIS | 35,630 | -1,33 % | Exelixis auf Barclays-Konferenz: Strategisches Wachstum und Einblicke in die Pipeline | ||
| SAREPTA THERAPEUTICS | 14,420 | +0,28 % | Mizuho raises Sarepta Therapeutics stock price target to $31 | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,148 | -1,15 % | PacBio Announces the Appointment of Chris Gibson to the Board of Directors | MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,900 | +2,16 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen |
Das Unternehmen DAY ONE BIOPHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 21,310 Euro und damit +0,12 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAY ONE BIOPHARMACEUTICALS INC finden Sie auf Wallstreet Online.